Login to Your Account

Amgen's $1B BioVex Buy May Signal More to Come

By Nuala Moran

Wednesday, January 26, 2011
LONDON – BioVex Group Inc. is to be acquired by Amgen Inc. in a cash sale that values the University College London spinout at up to $1 billion. There will be $425 million up front for the investors of the privately held cancer vaccines specialist, with $575 million in additional payments against regulatory and sales milestones.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription